Delivery strategies for antiparasitics

Expert Opinion on Investigational Drugs

Volumn 12, Issue 2, 2003, Pages 197-207

  Kayser, Oliver ^a   Kiderlen, Albrecht F ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Amphotericin B; Colloidal carriers; Drug delivery; Leishmaniasis; Liposomes; Malaria; Nanoparticles; Parasites; Surfactants

Indexed keywords

ADHESIVE AGENT; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; ANTIPARASITIC AGENT; ARTEMISININ; ATOVAQUONE; BENZETHONIUM CHLORIDE; BUPARVAQUONE; DIMETHYL SULFOXIDE; DRUG CARRIER; ERYTHROMYCIN; FLUCONAZOLE; HUMANTIN; IMPAVIDOR; KETOCONAZOLE; LIPOSOME; MELARSOPROL; MILTEFOSINE; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NPC 11612; NYSTATIN; OLEIC ACID; PAROMOMYCIN; PENICILLIN G; PENTAMIDINE; SOLID LIPID NANOPARTICLE; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA;

AFRICAN TRYPANOSOMIASIS; CRYPTOSPORIDIOSIS; DOSE RESPONSE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; EMULSION; HUMAN; LEISHMANIASIS; MACROMOLECULE; MALARIA; MICROEMULSION; MOUSE; NONHUMAN; PARASITOSIS; PHARMACOLOGICAL PARAMETERS; REVIEW; SCHISTOSOMIASIS;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; ANTIPARASITIC AGENTS; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; HUMANS; PARASITIC DISEASES; PULMONARY ALVEOLI; TRACHEA;

EID: 0037312923     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.2.197     Document Type: Review

References (86)

1. SHU YZ: Recent natural products based drug development: a pharmaceutical industry perspective. J. Nat. Rev. (1998) 61:1053-1071.
2. ALLSOP E: New antibiotic discovery, novel screens, novel targets and impact of microbial genomics. Curr. Opin. Microbiol. (1998) 1:530-534.
3. O'RIORDAN T, FARIS M: Inhaled antimicrobial therapy. Respir. Care Clin. N. Am. (1999) 5:617-631.
4. RIZZARDI GP, LAZZARIN A, MUSICCO M et al.: Better efficacy of twice-monthly than monthly aerosolised pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. An Italian multicentric randomised controlled trial. The Italian PCP Study Group. J. Infect. (1995) 31:99-105.
5. KREUTER J: Nanoparticles and microparticles for drug and vaccine delivery. J. Anat. (1996) 189:503-505.
6. BARRATT GM: Therapeutic applications of colloidal drug carriers. Pharm. Sci. Technol. Today (2000) 3:163-171.
7. LEE VHL, YANG JJ: Oral drug delivery. In: Drug Delivery and Targeting. A Hillery, A Lloyd, J Swarbrick (Eds), Taylor & Francis, London (2001):269-300.
8. FASANO A: Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol. (1998) 16:152-157.
9. VERMA RK, KRISHNA DM, GARG S: Formulation aspects in the development of osmotically controlled oral drug delivery systems. J. Control Release (2002) 79:7-27.
10. LAMBKIN I, PINILLA C: Targeting approaches to oral drug delivery. Expert Opin. Biol. Ther. (2002) 2:67-73.
11. KAYSER O: A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. Int. J. Pharm. (2001) 214:83-85.
12. MÜLLER RH, JACOBS C, KAYSER O: Nanosuspensions for the formulation of poorly soluble drugs. In: Pharmaceutical Emulsions and Suspensions. F Nielloud, G Marti-Mestres (Eds), Marcel Dekker, New York/Basel (2001):409-464.
13. ROBERTS MS, WALTERS K: The relationship between structure and barrier function of skin. In: Dermal Absorption and Toxicity Assessment. MS Roberts, K Walters (Eds), Marcel Dekker, New York/Basel (1998):1-42.
14. HADGRAFT J, PUGH WJ: The selection and design of topical and transdermal agents: a review. J. Invest. Dermatol. Symp. Proc. (1998) 3:131-135.
15. GAMIER T, CROFT SL: Topical treatment for cutaneous leishmaniasis. Curr. Opin. Invest. Drugs (2002) 3:538-544.
16. ABDI YA, GUSTAFSON LL, ERICSSON O, HELLGREN U: Handbook of drugs for Tropical Parasitic Infections. Taylor & Francis, Oxford, London (1995).
17. EL-ON J, LIVSHIN R, EVEN-PAZ Z, HAMBURGER D, WEINRAUCH L: Topical treatment of cutaneous leishmaniasis. J. Invest. Dermatol. (1986) 87:284-288.
18. SOTO J, FUYA P, HERRERA R, BERMAN J: Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin. Infect. Dis. (1998) 26:56-58.
19. NEAL RA, MURPHY AG, OLLIARO P, CROFT SL: Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (1994) 88:223-225.
20. BEN SALAH A, ZAKRAOUI H, ZAATOUR A et al.: A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am. J. Trop. Med. Hyg. (1995) 53:162-166.
21. ASILIAN A, JALAYER T, WHITWORTH JA, GHASEMI RL, NILFOROOSHZADEH M, OLLIARO P: A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am. J. Trop. Med. Hyg. (1995) 53:648-651.
22. SOTO JM, TOLEDO JT, GUTIERREZ P et al.: Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): Phase II pilot study. Am. J. Trop. Med. Hyg. (2002) 66:147-151.
23. ZVULUNOV A, KLAUS S, VARDY D: Fluconazole for the treatment of cutaneous leishmaniasis. N. Engl. J. Med. (2002) 347:370-371.
24. BRAJTBURG J, BOLARD J: Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. (1996) 9:512-531.
25. SCHMIDT-OTT R, KLENNER T, OVERATH P, ÄBISCHER T: Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (1999) 93:85-90.
26. TAYLOR G, KELLAWAY I: Pulmonary drug delivery. In: Drug Delivery and Targeting. A Hillery, A Lloyd, J Swarbrick (Eds), Taylor & Francis, London (2001):269-300.
27. NIVEN RW: Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst. (1995) 12:151-231.
28. SIMONDS AK, NEWMAN SP, JOHNSON MA, TALAEE N, LEE CA, CLARKE SW: Alveolar targeting of aerosol pentamidine. Toward a rational delivery system. Am. Rev. Respir. Dis. (1990) 141:827-829.
29. GUDE JK: Selective delivery of pentamidine to the lung by aerosol. Am. Rev. Respir. Dis. (1989) 139:1060.
30. KREUTER J: Colloidal Drug Delivery Systems. Marcel Dekker, Inc., New York (1994).
31. BETAGERI, GURU V, JENKINS, SCOTT A, PARSONS, DANIEL L: Liposome Drug Delivery Systems. Technomic Publishing Company, Lancaster, Pennsylvania, USA (1993).
32. MAURIN M, RAOULT D: Optimum treatment of intracellular infections. Drugs (1996) 52:45-59.
33. CUNNINGHAM AC: Parasitic adaptive mechanisms in infection by Leishmania. Exp. Mol. Pathol. (2002) 72:132-141.
34. BERMAN JD, EDWARDS N, KING M, GROGL M: Biochemistry of pentostam resistant Leishmania. Am. J. Trop. Med. Hyg. (1989) 40:159-164.
35. KREUTER J: Drug targeting with nanoparticles. Eur. J. Drug Metab. Pharmacokinet. (1994) 19:253-256.
36. MÜLLER RH, JACOBS C, KAYSER O: Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. (2001) 47:3-19.
37. PILENI, MP, TANORI, J, FILANKEMBO A: Biomimetic strategies for the control of size, shape and self-organization of nanoparticles. Colloid Surfaces A: Physicochem. Engineer. Aspects (1996) 123-124:561-573.
38. DOUGLAS SJ, DAVIS SS, ILLUM L: Nanoparticles in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. (1987) 3:233-261.
39. KREUTER J: Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. (2001) 47:65-81.
40. KREUTER J, SHAMENKOV D, PETROV V et al.: Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target. (2002) 10:317-325.
41. GESSNER A, OLBRICH C, SCHRÖDER W, KAYSER O, MÜLLER RH: The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int. J. Pharm. (2001) 214:87-91.
42. PAUL M, DURAND R. BOULARD Y et al: Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. J. Drug Target. (1998) 5:481-490.
43. GONZALEZ-MARTIN G, MERINO I, RODRIGUEZ-CABEZAS MN, TORRES M, NUNEZ R, OSUNA A. Characterization and trypanocidal activity of nifurtimox-containing and empty nanoparticles of polyethylcyanoacrylates. J. Pharm. Pharmacol. (1998) 50:29-35.
44. AHSAN F, RIVAS IP, KHAN MA, TORRES SUAREZ AI: Targeting to macrophages: role of physicochemical properties of particulate carriers - liposomes and microspheres - on the phagocytosis by macrophages. J. Control Release. (2002) 79:29-40.
45. SZOKA F Jr, PAPAHADJOPOULOS D: Comparative properties and methods of preparation of lipid vesicles (liposomes). Ann. Rev. Biophys. Bioeng. (1980) 9:467-508.
46. WONG-BERINGER A, JACOBS RA, GUGLIELMO BJ: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. (1998) 27:603-618.
47. COUVREUR P, FATTAL E, ANDREMONT A: Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm. Res. (1991) 8:1079-1086.
48. COUNE A: Liposomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience. Infection (1988) 16:141-147.
49. ALVING CR, STECK EA, CHAPMAN WL Jr, WAITS VB, HENDRICKS LD, SWARTZ GM Jr, HANSON WL: Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc. Natl. Acad. Sci. USA (1978) 75:2959-2963.
50. CROFT SL, YARDLEY V. Chemotherapy of leishmaniasis. Curr. Pharm. Des. (2002) 8:319-342.
51. MEDDA S, MUKHOPADHYAY S, BASU MK: Evaluation of the in vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal form. J. Antimicrob. Chemother. (1999) 44:791-794.
52. DUFFELS A, GREEN LG, LEY SV, MILLER AD: Synthesis of high-mannose type neoglycolipids: active targeting of liposomes to macrophages in gene therapy. Chemistry (2000) 14:1416-1430.
53. NAN A, NANAYAKKARA NP, WALKER LA, YARDLEY V, CROFT SL, GHANEHARI H: N-(2-hydroxapropyl)methacrylamide (HPMA) copolymers for targeted delivery of 8-aminoquinoline antileishmanial drugs. J. Control. Release (2001) 77:233-243.
54. PAPAHADJOPOULOS D, VAIL WJ, JACOBSON K, POSTE G: Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim. Biophys. Acta (1975) 394:483-491.
55. WALKER SA, KENNEDY MT, ZASADZINSKI JA: Encapsulation of bilayer vesicles by self-assembly. Nature (1997) 387:61-64.
56. SANTANGELO R, PADERU P, DELMAS G et al.: Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob. Agents Chemother. (2000) 44:2356-2360.
57. MARTI-MESTRES G, NIELLOUD F: Main surfactants used in the pharmaceutical field. In: Pharmaceutical Emulsions and Suspensions. F Nielloud, G Marti-Mestres (Eds), Marcel Dekker, New York/Basel (2000):1-18.
58. BUSZELLO K, MÜLLER BW. Emulsions as drug delivery systems. In: Pharmaceutical Emulsions and Suspensions. F Nielloud, G Marti-Mestres (Eds), Marcel Dekker, New York/Basel (2000):191-228.
59. GANGNEUX JP, SULAHIAN A, GARIN YJ, FARINOTTI R, DEROUIN F: Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of Am Bisome. Antimicrob. Agents Chemother. (1996) 40:1214-1218.
60. CHAVANET P: Amphotericin B deoxycholate (Fungizone): old drug, new versions. Rev. Med. Interne (1997) 18:153-165.
61. CARTER KC, MULLEN AB, SUNDAR S, KENNEY RT. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani. Antimicrob. Agents Chemother. (2001) 45:3555-3559.
62. WASHINGTON C, LANCE M, DAVIS SS: Toxicity of amphotericin B emulsion formulations. J. Antimicrob. Chemother. (1993) 31:806-808.
63. Polymeric Drugs And Drug Delivery Systems. RL Dunn, RM Ortenbrite (Eds), American Chemical Society, Washington DC, USA (1991).
64. SMITH A, HUNNEYBALL IM: Evaluation of poly(lactic acid) as biodegradable drug delivery system for parenteral administration. Int. J. Pharm. (1986) 36:215-220.
65. BAILLIE AJ, COOMBS GH, DOLAN TF et al.: Biodegradable microspheres: polyacryl starch microparticles as a delivery system for the antileishmanial drug, sodium stibogluconate. J. Pharm. Pharmacol. (1987) 39:832-835.
66. VENIER-JULIENNE MC, BENOIT JP: Preparation, purification and morphology of polymeric nanoparticles as drug carriers. Pharm. Acta Helv. (1996) 71:121-128.
67. MANDAL TK: Effect of solvent on the characteristics of pentamidine loaded microcapsule. J. Biomater. Sci. Polym. Ed. (1999) 10:1-17.
68. GONZALEZ-MARTIN G, FIGUEROA C, MERINO I, OSUNA A: Allopurinol encapsulated in polycyanoacrylate nanoparticles as potential lysosomatropic carrier: preparation and trypanocidal activity. Eur. J. Pharm. Biopharm. (2000) 49:137-142.
69. LEES RE: Trial of an enteric-coated preparation of lucanthone hydrochloride in Schistosoma mansoni infection. Trans. R. Soc. Trop. Med. Hyg. (1967) 61:806-811.
70. KATZ N, PELLEGRINO J, OLIVEIRA CA: Further clinical trials with hycanthone, a new antischistosomal agent. Am. J. Trop. Med. Hyg. (1969) 18:924-929.
71. ZHU DY, FU S, WU WL, QIAN YD, FENG MY, WANG MJ: Comparative study of two kinds of enteric-coated furapromidum with rectal dipterex in treatment for schistosomiasis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao (1980) 2:277-278.
72. MARITZ JC: Hycanthone therapy in bilharziasis. S. Afr. Med. J. (1970) 44:126-128
73. RINGWALD P, BICKII J, SAME-EKOBO A, BASCO LK: Pyronaridine for treatment of Plasmodium ovale and Plasmodium malariae infections. Antimicrob. Agents Chemother. (1997) 41:2317-2319.
74. HUANG ZS, FENG Z, MENG F et al.: Therapeutic effect of pyronaridine in plain tablets and enteric-coated tablets in falciparum malaria patients. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (1989) 7:19-21.
75. GHOSAL S, KRISHNAPRASAD BN, KHANNA M et al.: 3′-deoxyribonucleosides and their derivatives as anti-amoebic agents. Int. J. Pharm. (2000) 194:15-20.
76. SCHENONE H, VILLARROEL F, SCHENONE L, GALDAMES M, ROMERO E, JIMENEZ M: Treatment of infections by Entamoeba histolytica and Giardia lamblia with different dosages of 100 mg tinidazole enteric coated tablets. Bol. Chil. Parasitol. (1979) 34:2-6.
77. BUCKTON G: Interfacial Phenomena in Drug Delivery and Targeting. Harwood Academic Publishers (1995).
78. BOLARD J, ANDREMONT A: Lipid formulations of amphotericin B: from clinical trials to in vitro studies. In: Liposomes, New Systems and New Trends in their Application. F Puisieux, P Couvreur, J Delattre, JP Devissaguet (Eds), Editions de Sánte, Paris (1995):397-428.
79. GELDERBLOM H, VERWEIJ J, NOOTER K, SPARREBOOM A, CREMOPHOR EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer (2001) 37:1590-1598.
80. ALBERS E, MÜLLER BW: Cyclodextrin derivatives in pharmaceutics. Crit. Rev. Ther. Drug Carrier Syst. (1995) 12:311-337.
81. WONG JW, YUEN KH: Improved oral bioavailability of artemisinin through inclusion complexation with beta- and gamma-cyclodextrins. Int. J. Pharm. (2001) 227:177-185.
82. MULLEN AB, CARTER KC, BAILLIE AJ: Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob. Agents Chemother. (1997) 41:2089-2092.
83. JUST-NUBLING G: Therapy of candidiasis and cryptococcosis in AIDS. Mycoses (1994) 37(Suppl. 2):56-63.
84. CASTRO-HERMIDA JA, GONZALEZ-LOSADA Y, FREIRE-SANTOS F, MEZO-MENENDEZ M, ARES-MAZAS E: Evaluation of beta-cyclodextrin against natural infections of cryptosporidiosis in calves. Vet. Parasitol. (2001) 101:85-89.
85. McKELLAR QA: Chemotherapy and delivery systems - helminths. Vet. Parasitol. (1994) 54:249-258.
86. ANDERSON N, LABY RH, PRICHARD RK, HENNESSY D: Controlled release of anthelmintic drugs: a new concept for prevention of helminthiasis in sheep. Res. Vet. Sci. (1980) 29:333-341.